Ono Pharmaceutical Co. Ltd
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules f… Read more
Ono Pharmaceutical Co. Ltd (OPHLF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.038x
Based on the latest financial reports, Ono Pharmaceutical Co. Ltd (OPHLF) has a cash flow conversion efficiency ratio of 0.038x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($32.10 Billion) by net assets ($846.09 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Ono Pharmaceutical Co. Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Ono Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Ono Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ono Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Inari Medical Inc
NASDAQ:NARI
|
0.006x |
|
Urban Outfitters Inc
NASDAQ:URBN
|
0.023x |
|
Edenred SA
PA:EDEN
|
0.129x |
|
Shenzhen Woer Heat-Shrinkable Material Co Ltd
SHE:002130
|
0.044x |
|
Skyline Corporation
NYSE:SKY
|
0.063x |
|
Mueller Water Products
NYSE:MWA
|
0.060x |
|
Alkermes Plc
NASDAQ:ALKS
|
0.093x |
|
BB Seguridade Participacoes SA
PINK:BBSEY
|
-0.371x |
Annual Cash Flow Conversion Efficiency for Ono Pharmaceutical Co. Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Ono Pharmaceutical Co. Ltd from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $788.20 Billion | $82.46 Billion | 0.105x | -24.50% |
| 2024-03-31 | $798.61 Billion | $110.66 Billion | 0.139x | -35.08% |
| 2023-03-31 | $747.81 Billion | $159.61 Billion | 0.213x | +128.41% |
| 2022-03-31 | $661.67 Billion | $61.83 Billion | 0.093x | -19.01% |
| 2021-03-31 | $641.16 Billion | $73.98 Billion | 0.115x | -11.62% |
| 2020-03-31 | $568.02 Billion | $74.16 Billion | 0.131x | +10.02% |
| 2019-03-31 | $562.74 Billion | $66.77 Billion | 0.119x | +299.59% |
| 2018-03-31 | $529.62 Billion | $15.73 Billion | 0.030x | -79.09% |
| 2017-03-31 | $524.21 Billion | $74.45 Billion | 0.142x | +426.70% |
| 2016-03-31 | $476.25 Billion | $12.84 Billion | 0.027x | -59.42% |
| 2015-03-31 | $475.21 Billion | $31.58 Billion | 0.066x | +5.68% |
| 2014-03-31 | $452.00 Billion | $28.42 Billion | 0.063x | +69.96% |
| 2013-03-31 | $423.29 Billion | $15.66 Billion | 0.037x | -31.43% |
| 2012-03-31 | $400.97 Billion | $21.63 Billion | 0.054x | -28.55% |
| 2011-03-31 | $394.57 Billion | $29.80 Billion | 0.076x | +43.97% |
| 2010-03-31 | $406.11 Billion | $21.30 Billion | 0.052x | -16.58% |
| 2009-03-31 | $390.04 Billion | $24.52 Billion | 0.063x | -25.92% |
| 2008-03-31 | $430.26 Billion | $36.52 Billion | 0.085x | -1.95% |
| 2007-03-31 | $446.81 Billion | $38.68 Billion | 0.087x | -3.82% |
| 2006-03-31 | $443.63 Billion | $39.93 Billion | 0.090x | +22.11% |
| 2005-03-31 | $391.43 Billion | $28.85 Billion | 0.074x | -- |